Rostislav Christov Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 2,431 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of C$7.45, for a total value of C$18,115.81.

Rostislav Christov Raykov also recently made the following trade(s):

• On Monday, July 1st, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$6.13, for a total value of C$14,902.03.

Fennec Pharmaceuticals Stock Performance

Shares of TSE:FRX opened at C$7.14 on Friday. The business’s 50-day simple moving average is C$8.17 and its 200 day simple moving average is C$10.59. The company has a market cap of C$195.35 million, a P/E ratio of 79.33 and a beta of 0.26. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02. Fennec Pharmaceuticals Inc. has a one year low of C$7.00 and a one year high of C$15.43.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The firm had revenue of C$9.94 million during the quarter, compared to analyst estimates of C$18.67 million. On average, sell-side analysts forecast that Fennec Pharmaceuticals Inc. will post 0.6058577 earnings per share for the current fiscal year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.